Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment)

被引:66
|
作者
Joshi, P [1 ]
Prasad, VR [1 ]
机构
[1] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
关键词
D O I
10.1128/JVI.76.13.6545-6557.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
RNA aptamers derived by SELEX (systematic evolution of ligands by exponential enrichment) and specific for human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) bind at the template-primer cleft with high affinity and inhibit its activity. In order to determine the potential of such template analog RT inhibitors (TRTIs) to inhibit HIV-1 replication, 10 aptamers were expressed with flanking, self-cleaving ribozymes to generate aptamer RNA transcripts with minimal flanking sequences. From these, six aptamers (70.8,13, 70.15, 80.55,65, 70.28, 70.2804, and 1.1) were selected based on binding constants (K-d) and the degree of inhibition of RT in vitro (50% inhibitory concentration [IC50]). These six aptamers were each stably expressed in 293T cells followed by transfection of a molecular clone of HIVR3B. Analysis of the virion particles revealed that the aptamers were encapsidated into the virions released and that the packaging of the viral genomic RNA or the cognate primer, tRNA(3)(Lys), was apparently unaffected. Infectivity of virions produced from 293T cell lines expressing the aptamers, as measured by infecting LuSIV reporter cells, was reduced by 90 to 99.5% compared to virions released from cells not expressing any aptamers. PCR analysis of newly made viral DNA upon infection with virions containing any of the three aptamers with the strongest binding affinities (70.8,13, 70.15, and 80.55,65) showed that all three were able to form the minus-strand strong-stop DNA. However, virions with the aptamers 70.8 and 70.15 were defective for first-strand transfer, suggesting an early block in viral reverse transcription. Jurkat T cells expressing each of the three aptamers, when infected with HIVR3B, completely blocked the spread of HIV in culture. We found that the replication of nucleoside analog RT inhibitor-, normucleoside analog RT inhibitor-, and protease inhibitor- resistant viruses was strongly suppressed by the three aptamers. In addition, some of the HIV subtypes were severely inhibited (subtypes A, B, D, E, and F), while others were either moderately inhibited (subtypes C and O or were naturally resistant to inhibition (chimeric A/D subtype). As virion-encapsidated TRTIs can predispose virions for inhibition immediately upon entry, they should prove to be efficacious agents in gene therapy approaches for AIDS.
引用
收藏
页码:6545 / 6557
页数:13
相关论文
共 50 条
  • [21] BENZOPHENONE DERIVATIVES - A NOVEL SERIES OF POTENT AND SELECTIVE INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE
    WYATT, PG
    BETHELL, RC
    CAMMACK, N
    CHARON, D
    DODIC, N
    DUMAITRE, B
    EVANS, DN
    GREEN, DVS
    HOPEWELL, PL
    HUMBER, DC
    LAMONT, RB
    ORR, DC
    PLESTED, SJ
    RYAN, DM
    SOLLIS, SL
    STORER, R
    WEINGARTEN, GG
    JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (10) : 1657 - 1665
  • [22] Strained template under the thumbs - How reverse transcriptase of human immunodeficiency virus type 1 moves along its template
    Hermann, T
    Heumann, H
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 242 (01): : 98 - 103
  • [23] INTERACTION BETWEEN RIFABUTIN AND HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 - INHIBITION OF REPLICATION, CYTOPATHIC EFFECT, AND REVERSE-TRANSCRIPTASE INVITRO
    ANAND, R
    MOORE, JL
    CURRAN, JW
    SRINIVASAN, A
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) : 684 - 688
  • [24] Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation
    Pinto, LA
    Blazevic, V
    Patterson, BK
    Mac Trubey, C
    Dolan, MJ
    Shearer, GM
    JOURNAL OF VIROLOGY, 2000, 74 (10) : 4505 - 4511
  • [25] Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1
    Balzarini, J
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (09) : 921 - 944
  • [26] Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors:: genotypic and phenotypic testing
    García-Lerma, JG
    Heneine, W
    JOURNAL OF CLINICAL VIROLOGY, 2001, 21 (03) : 197 - 212
  • [27] Rational Approaches for the Design of Effective Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitors
    Ribone, Sergio R.
    Quevedo, Mario A.
    Madrid, Marcela
    Brinon, Margarita C.
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2011, 51 (01) : 130 - 138
  • [28] NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS AND RESISTANCE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    JOHNSON, VA
    JOURNAL OF INFECTIOUS DISEASES, 1995, 171 : S140 - S149
  • [29] Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones
    Didierjean, J
    Isel, C
    Querré, F
    Mouscadet, JF
    Aubertin, AM
    Valnot, JY
    Piettre, SR
    Marquet, R
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) : 4884 - 4894
  • [30] SUBSTRATE-INHIBITION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE
    FURMAN, PA
    PAINTER, G
    WILSON, JE
    CHENG, N
    HOPKINS, S
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (14) : 6013 - 6017